Bayer banks €3bn in Apollo contraceptives division deal

Bayer has sold a involvement successful its recently established contraceptives offshoot to planetary plus absorption steadfast Apollo for €3bn ($3.4bn) – allowing the institution to entree funds without relinquishing wide power of the business.

Through this agreement, Apollo volition unafraid a minority, non-controlling involvement successful the German beingness sciences giant's long-acting reversible contraceptives (LARC) business, which volition location the company's marketed options specified arsenic hormonal intrauterine devices (IUD), Mirena, Jaydess and Kyleena, arsenic good arsenic precocious arm-based implant, Jadelle.

While Apollo volition ain a involvement successful Bayer's LARC concern if the transaction closes arsenic expected successful Q3 2026, the German beingness sciences elephantine volition inactive person implicit operational power implicit the business, and determination volition beryllium nary changes to its strategy oregon activities – which volition proceed to autumn nether the remit of Bayer Pharmaceuticals Division's halfway operations.

According to Bayer's CFO, Dr Judith Hartmann, the woody volition lend to the strengthening of the company's superior structure, portion allowing it to clasp power implicit an facet of its pharmaceutical concern which she deems arsenic "core" to Bayer's offering.

"It [the Apollo deal] enhances our fiscal flexibility arsenic we negociate accrued liquidity requirements this twelvemonth related to enslaved maturities and litigation procedures, portion continuing to execute our semipermanent priorities," Hartmann added.

Bayer inks this woody with Apollo aft the institution took a fiscal deed from a long-standing litigation implicit its glyphosate-based weed killer, Roundup, which has been astatine the centre of respective litigations owed to its alleged nexus to cancer. The German pharma elephantine primitively absorbed the rights to Roundup done its $63bn Monsanto buyout, which closed successful 2018.

Bayer joins the pharma dealmaking spree

As Bayer looks to restructure and unafraid its semipermanent maturation prospects, the institution has breached its pharma dealmaking stagnation by orchestrating the $2.45bn takeover of ophthalmology specializer Perfuse Therapeutics, which is processing a cause that Bayer hopes volition heighten the bequest of its Regeneron co-developed blockbuster therapy, Eylea (aflibercept).

This comes arsenic Bayer places pharmaceuticals astatine the halfway of its maturation strategy, with the modulation distant from older blockbusters towards much specialised therapies constituting a cardinal operator of worth for the company, according to an nonfiction published successful Ad Hoc News.

Bayer is not the lone institution engaging successful dealmaking enactment to beforehand semipermanent maturation successful the pharma sector, however, arsenic companies from crossed the abstraction ink multi-billion dollar deals to fortify their pipelines, adhd caller medicines to their portfolios and diversify their offerings.